Bicycle Therapeutics (NASDAQ:BCYC – Get Rating) released its quarterly earnings results on Thursday. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.25), MarketWatch Earnings reports. Bicycle Therapeutics had a negative net margin of 568.71% and a negative return on equity of 35.59%.
Bicycle Therapeutics stock traded down $1.20 during midday trading on Friday, reaching $20.44. 708,533 shares of the stock traded hands, compared to its average volume of 1,046,911. The stock’s fifty day moving average is $35.62 and its 200-day moving average is $46.80. Bicycle Therapeutics has a 12 month low of $19.99 and a 12 month high of $62.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 12.65 and a quick ratio of 12.65.
Several research firms have issued reports on BCYC. Zacks Investment Research lowered Bicycle Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Needham & Company LLC cut their price target on Bicycle Therapeutics from $85.00 to $75.00 and set a “buy” rating for the company in a report on Tuesday, April 12th. B. Riley lowered Bicycle Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $62.00 to $33.00 in a report on Wednesday, April 13th. Morgan Stanley initiated coverage on Bicycle Therapeutics in a report on Monday, February 14th. They set an “equal weight” rating and a $60.00 price target for the company. Finally, TheStreet lowered Bicycle Therapeutics from a “c-” rating to a “d+” rating in a research note on Thursday, April 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $65.08.
Bicycle Therapeutics Company Profile (Get Rating)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
- Get a free copy of the StockNews.com research report on Bicycle Therapeutics (BCYC)
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.